A long-acting 3TC ProTide nanoformulation suppresses HBV replication in humanized mice.

Weimin Wang, Nathan Smith, Edward Makarov, Yimin Sun, Catherine L Gebhart, Murali Ganesan, Natalia A Osna, Howard E Gendelman, Benson J Edagwa, Larisa Y Poluektova

Nanomedicine : nanotechnology, biology, and medicine 2020 Aug

filter terms:

Nowadays, there is a strong request for the treatment of chronic HBV-infection with direct acting antivirals. Furthermore, prevalent human immunodeficiency virus (HIV-1) and hepatitis B (HBV) co-infections highlight an immediate need for dual long-acting and easily administered antivirals. To this end, we modified lamivudine (3TC), a nucleoside analog inhibitor of both viruses, into a lipophilic monophosphorylated prodrug (M23TC). Prior work demonstrated that nanoformulation of M23TC (NM23TC) enhanced drug stability, controlled dissolution and improved access to sites of viral replication. The present study evaluated the efficacy of a NM23TC in HBV-infected chimeric liver humanized mice. Levels of HBV DNA and HBsAg in plasma were monitored up to 8 weeks posttreatment. A single intramuscular dose of 75 mg/kg 3TC equivalents of nanoformulated NM23TC provided sustained drug levels and suppressed HBV replication in humanized mice for 4 weeks. The results support further development of this long-acting 3TC nanoformulation for HBV treatment and prevention. Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Citation

Weimin Wang, Nathan Smith, Edward Makarov, Yimin Sun, Catherine L Gebhart, Murali Ganesan, Natalia A Osna, Howard E Gendelman, Benson J Edagwa, Larisa Y Poluektova. A long-acting 3TC ProTide nanoformulation suppresses HBV replication in humanized mice. Nanomedicine : nanotechnology, biology, and medicine. 2020 Aug;28:102185